I call the meeting to order. I want to thank the witnesses for coming forward, and we'll ask the members who are in the room to take their seats so we can get started.
First of all, this is the fourth meeting we've had on the CDR, the common drug review, with the beginning of our series on prescription drugs.
The witnesses today are from Cancer Care Ontario, the Cancer Advocacy Coalition of Canada, Princess Margaret Hospital, Canadian Breast Cancer Network, and the Colorectal Cancer Association of Canada. We'll start with Debbie Milliken from Cancer Care Ontario.
I want to thank the rest of the panel for being here. I'll introduce you as I yield you the floor, but we'll start the meeting with you, Ms. Milliken.